CD8A and neoplasm: Further, NeoAg and anti-PD-1 coadministration significantly increased the number of total CD8+ T cells within tumor-infiltrating lymphocyte (TIL) fractions when isolated at the day 17 effector phase after the first round of immunotherapy, whereas conventional (Tconv) and regulatory (Treg) CD4+ T cell numbers remain unchanged (Figure 7F).